1858 Wealth Management LLC Purchases New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

1858 Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 314 shares of the biopharmaceutical company’s stock, valued at approximately $224,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Avitas Wealth Management LLC grew its position in Regeneron Pharmaceuticals by 12.7% during the fourth quarter. Avitas Wealth Management LLC now owns 372 shares of the biopharmaceutical company’s stock valued at $265,000 after buying an additional 42 shares during the period. Redwood Wealth Management Group LLC boosted its stake in shares of Regeneron Pharmaceuticals by 4.2% during the 4th quarter. Redwood Wealth Management Group LLC now owns 497 shares of the biopharmaceutical company’s stock worth $354,000 after acquiring an additional 20 shares in the last quarter. Ninety One UK Ltd grew its position in shares of Regeneron Pharmaceuticals by 14.4% during the 4th quarter. Ninety One UK Ltd now owns 78,005 shares of the biopharmaceutical company’s stock valued at $55,565,000 after acquiring an additional 9,820 shares during the period. E. Ohman J or Asset Management AB increased its stake in shares of Regeneron Pharmaceuticals by 12.2% in the 4th quarter. E. Ohman J or Asset Management AB now owns 4,970 shares of the biopharmaceutical company’s stock valued at $3,540,000 after purchasing an additional 540 shares in the last quarter. Finally, Calamos Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 86.7% in the 4th quarter. Calamos Advisors LLC now owns 22,658 shares of the biopharmaceutical company’s stock worth $16,140,000 after purchasing an additional 10,523 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on REGN. Piper Sandler cut their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research report on Monday, January 27th. Bank of America reissued an “underperform” rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Citigroup reduced their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Barclays lowered their price objective on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Finally, TD Cowen decreased their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research report on Tuesday. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $983.65.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $697.05 on Wednesday. The company’s 50-day moving average is $719.16 and its two-hundred day moving average is $918.90. Regeneron Pharmaceuticals, Inc. has a 1-year low of $642.00 and a 1-year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The firm has a market capitalization of $76.60 billion, a price-to-earnings ratio of 17.25, a PEG ratio of 1.60 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $11.86 EPS. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.75 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.50%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.